Ciprofloxacin-encapsulated poly(dl-lactide-co-glycolide) nanoparticles and its antibacterial activity

International Journal of Pharmaceutics

Volumn 352, Issue 1-2, 2008, Pages 317-323

  Jeong, Young Il ^a   Na, Hee Sam ^b   Seo, Dong Hyuk ^a   Kim, Dong Gon ^a   Lee, Hyun Chul ^b   Jang, Mi Kyeong ^a   Na, Sang Kwon ^a   Roh, Sung Hee ^c   Kim, Sun Il ^c   Nah, Jae Woon ^a  

^a Sunchon National University   (South Korea)

^b Chonnam National University Medical School   (South Korea)

^c Chosun University   (South Korea)

Author keywords

Animal infection model; Ciprofloxacin HCl; Nanoparticles; Poly(dl lactide co glycolide); Sustained release

Indexed keywords

CIPROFLOXACIN; NANOPARTICLE; POLYGLUTAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; CONTROLLED STUDY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; EMULSION; ESCHERICHIA COLI; EVAPORATION; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; CIPROFLOXACIN; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; ESCHERICHIA COLI; KINETICS; LACTIC ACID; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 39549092805     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.11.001     Document Type: Article

References (22)

1. Appelbaum P.C., and Hunter P.A. The fluoroquinolone antibacterials: past, present, and future perspective. Int. J. Antimicrob. Agents 16 (2000) 5-15
2. Barnett B.J., and Stephens D.S. Urinary tract infection: an overview. Am. J. Med. Sci. 314 (1997) 245-249
3. Davis R., Markham A., and Balfour J.A. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy, and tolerability. Drugs 51 (1996) 1019-1074
4. Dillen K., Vandervoort J., Van den Mooter G., Verheyden L., and Ludwig A. Factorial design, physicochemical characterization and activity of ciprofloxacin-PLGA nanoparticles. Int. J. Pharm. 275 (2004) 171-187
5. Emmerson A.M. The role of the skin in nosocominal infection: a review. J. Chemother. 1 (1989) 12-18
6. Fihn S.D. Clinical practice. Acute uncomplicated urinary tract infaction in women. New Engl. J. Med. 349 (2003) 259-266
7. Fontana G., Pitarresi G., Tomarchio V., Carlisi B., and San Biagio P.L. Preparation, characterization and in vitro antimicrobial activity of ampicillin-loaded polyethylcyanoacrylate nanoparticles. Biomaterials 19 (1998) 1009-1017
8. Fontana G., Licciardi M., Mansueto S., Schillaci D., and Giammona G. Amoxicillin-loaded polyethylcyanoacrylate nanoparticles: influence of PEG coating on the particle size, drug release rate and phagocytic uptake. Biomaterials 22 (2001) 2857-2865
9. Henry Jr. D.C., Bettis R.B., Riffer E., Haverstock D.C., Kowalsky S.F., Manning K., Hamed K.A., and Church D.A. Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women. Clin. Ther. 24 (2002) 2088-2104
10. Hooton T.M. The current management strategies for community-acquired urinary tract infection. Infect. Dis. Clin. North Am. 17 (2003) 303-332
11. Ma Z., Ma L., Gao C., and Shen J. Preformed microcapsules for loading and sustained release of ciprofloxacin hydrochloride. J. Control. Rel. 104 (2005) 193-202
12. Mourani C., Hagge G., Mallat S.G., Chehab G., and Sabbagh M. Salmonella typhi in a child with urinary tract infection and urolithiasis. J. Med. Liban. 53 (2005) 234-235
13. Na, H.S., Lee, H.C., in preparation. Animal model of local infection using dialysis membrane tubing and its treatment sustained release antibiotic nanoparticles.
14. Naber K.G., Bergman B., Bishop M.C., and Urinary tract infection (UTI). Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). EAU guidelines for the management of urinary and male genital tract infections. Eur. Urol. 40 (2001) 576-588
15. National Committee for Clinical Laboratory Standards, 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically-sixth edition: Approved Standard M7-A6, 15, NCCLS, Wayne, PA, USA.
16. Page-Clisson M.E., Pinto-Alphandary H., Ourevitch M., Andremont A., and Couvreur P. Development of ciprofloxacin-loaded nanoparticles: physicochemical study of the drug carrier. J. Control. Rel. 56 (1998) 23-32
17. Page-Clisson M.E., Pinto-Alphandary H., Chachaty E., Couvreur P., and Andremont A. Drug targeting by polyalkylcyanoacrylate nanoparticles is not efficient against persistent Salmonella. Pharm. Res. 15 (1998) 544-549
18. Ramchandani M., and Robinson D. In vitro and in vivo release of ciprofloxacin from PLGA 50:50 implants. J. Control. Rel. 54 (1998) 167-175
19. Stratton C. Fluoroquinolone antibiotics: properties of the class and individual agents. Clin. Ther. 14 (1992) 348-375
20. Talan D.A., Naber K.G., Palou J., and Elkharrat D. Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections. Int. J. Antimicrob. Agents 23S1 (2004) S54-S66
21. Wagenlehner F.M.E., Kinzig-Schippers M., Sörgel F., Weidner W., and Naber K.G. Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. Int. J. Antimicrob. Agents 28 (2006) 551-559
22. Warren J.W., Abrutyn E., Hebel J.R., Johnson J.R., Schaeffer A.J., and Stamm W.E. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Disease Society of America (IDSA). Clin. Infect. Dis. 29 (1999) 745-758